title: Impact of rituximab and IPI on survival in diffuse large B cell lymphoma patients treated at a tertiary level cancer centre in Pakistan: a single-centre experience.
abstract: OBJECTIVE
  To determine the impact of Rituximab and international prognostic index score on survival in diffuse large B-cell lymphoma patients.
  
  
  METHODS
  The retrospective study was conducted at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, from January to May 2013 and comprised record of patients with diffuse large B-cell lymphoma who were treated from 2007 to 2010. Baseline international prognostic index score, stage at presentation were noted and the records were divided into two groups A and B on the basis of the type of chemotherapy. SPSS 19 was used for statistical analysis.
  
  
  RESULTS
  Of the 93 patients in the study whose records were reviewed, 54(58%) were men. Overall median age was 43 years (range: 18-76). Stages at presentation were stage-I 14 (15.1%), stage-II 41 (44.1%), stage-III 20 (21.5%) and stage-lV 18 (19.4%). International prognostic index risk categorisation was low risk 59 (63.4%), low intermediate risk 23 (24.7%), high intermediate risk 10 (10.8%) and high risk 1 (1.1%). There were 31 (33%) patients in Group A and 62 (67%) in Group B. Median follow-up was 3.9 years (range: 1.2-6.1). Overall survival at 4 years was 66.4%; for Group A 65.3% and for Group B 66.7% (p < 0.4). On the basis of risk categories, overall survival was statistically significant (p < 0.001) between the groups.
  
  
  CONCLUSIONS
  International prognostic index risk categorisation had statistically significant impact on survival. However, there was no evidence of a significant survival benefit between types of chemotherapy. Further controlled trials are needed in this regard.
authors.forename: Sohail
authors.initials: S
authors.lastname: Athar
authors.forename: Neelam
authors.initials: N
authors.lastname: Siddiqui
authors.forename: Sulaman Raza
authors.initials: SR
authors.lastname: Rai
authors.forename: Narjis
authors.initials: N
authors.lastname: Muzaffar
authors.forename: Abdul
authors.initials: A
authors.lastname: Hameed
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015331:Cohort Studies; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010154:Pakistan; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012189:Retrospective Studies; D000069283:Rituximab; D062606:Tertiary Care Centers; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone